Group 1 - The company, 港通医疗, announced a reduction in credit impairment losses and asset impairment losses totaling approximately 21.27 million yuan for the first half of 2025, which will correspondingly decrease the company's total profit and owners' equity for that period [1] - For the first half of 2025, the revenue composition of 港通医疗 is as follows: medical clean equipment and systems account for 55.69%, medical gas equipment and systems account for 37.3%, sales of medical devices and other products account for 4.06%, operation and maintenance services account for 2.81%, and other businesses account for 0.14% [1]

Core Viewpoint - The financial performance of Kangtong Medical in the first half of 2025 shows significant declines in revenue and net profit, indicating potential challenges for the company moving forward [1][2]. Financial Performance - The company's revenue for the first half of 2025 was 265 million yuan, a year-on-year decrease of 39.29% [1]. - The net profit attributable to shareholders was -8.4044 million yuan, a year-on-year decline of 154.53% [1]. - The basic earnings per share were -0.09 yuan [1]. - The gross profit margin for the first half of 2025 was 22.09%, an increase of 3.65 percentage points year-on-year [2]. - The net profit margin was -3.45%, a decrease of 6.97 percentage points compared to the same period last year [2]. Cost Structure - Total operating expenses for the first half of 2025 were 48.8419 million yuan, a decrease of 2.3451 million yuan year-on-year [2]. - The expense ratio was 18.41%, an increase of 6.70 percentage points year-on-year [2]. - Sales expenses decreased by 24.03%, while management expenses increased by 12.24% [2]. Shareholder Information - As of the end of the first half of 2025, the total number of shareholders was 8,154, a decrease of 301 from the previous quarter, representing a decline of 3.56% [3]. - The average market value per shareholder increased from 220,200 yuan to 249,300 yuan, an increase of 13.21% [3]. Business Overview - Kangtong Medical, established on January 13, 1998, is located in Chengdu, Sichuan Province, and was listed on July 25, 2023 [3]. - The company's main business involves providing medical institutions with overall solutions centered on medical gas systems and clean surgical departments [3]. - The revenue composition includes: 55.69% from clean medical equipment and systems, 37.30% from medical gas equipment and systems, 4.06% from medical devices and other product sales, 2.81% from operation and maintenance services, and 0.14% from other sources [3].

四川港通医疗设备集团股份有限公司（以下简称"公司"）第五届董事会第 四次会议于 2025 年 8 月 27 日在公司会议室以现场及通讯方式召开。本次会议通 知于 2025 年 8 月 25 日以通讯方式送达全体董事。本次会议应出席董事 9 人，实 际出席董事 9 人（其中：陈兴根先生、魏勇先生、陈叙先生、姚刚先生、赵尘女 士、周正女士以通讯表决方式出席会议）。会议由董事长陈永先生召集并主持， 高级管理人员列席了本次会议。本次会议的召集、召开符合《公司法》和《公司 章程》的有关规定，会议合法有效。 证券代码：301515 证券简称：港通医疗 公告编号：2025-048 四川港通医疗设备集团股份有限公司 第五届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （二）审议通过《关于<2025 年半年度募集资金存放与使用情况的专项报告> 的议案》 董事会认为：公司募集资金的存放与使用情况符合中国证监会、深圳证券交 一、董事会会议审议情况 经过各位董事认真审议，本次会议形成如下决议： （一）审议通过《关于公司<2025 年半年度报告>全文及其摘要 ...

四川港通医疗设备集团股份有限公司 2025年半年度募集资金存放与使用情况的专项报告 根据《上市公司募集资金监管规则》和《深圳证券交易所上市公司自律监管指 引第2号-创业板上市公司规范运作》等有关规定，现将本公司2025年半年度募集资 金存放与使用情况说明如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监许可〔2023〕1108号文同意注册，并经深圳证 券交易所同意，本公司由主承销商中信建投证券股份有限公司通过深圳证券交易所 系统于2023年7月11日采用网上发行，网下配售，战略投资者配售方式，向社会公众 公开发行了普通股（A股）股票2,500.00万股，发行价为每股人民币31.16元。截至 2023年7月17日，本公司共募集资金779,000,000.00元，扣除发行费用89,004,023.26 元后，募集资金净额为689,995,976.74元。 上述募集资金净额已经致同会计师事务所（特殊普通合伙）致同验字（2023） 第510C000333号《验资报告》验证。 （二）以前年度已使用金额、本报告期使用金额及当前余额 1、以前年度已使用金额 截至2024年12月 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-051 四川港通医疗设备集团股份有限公司 关于 2025 年半年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 8 月 26 日召开第五届董事会审计委员会第一次会议，于 2025 年 8 月 27 日召开第五届董事会第四次会议，审议通过《关于 2025 年半年度计提资产减值准 备的议案》。现将相关事宜公告如下： 一、本次计提减值准备的情况概述 根据《企业会计准则》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及公司会计 政策等规定，为客观、公允地反映公司截至 2025 年 6 月 30 日的财务状况及经营 成果，公司本着谨慎性原则，对 2025 年半年度合并财务报表范围内可能发生减值 迹象的资产进行全面清查和减值测试，对存在减值迹象的资产计提相应减值准备。 二、本次计提减值准备的范围和总金额 2025 年 1—6 月，公司计提 ...

四川港通医疗设备集团股份有限公司 2025 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | 非经营性资金占用 | 资金占用方 | 占用方与上市 公司的关联关 | 上市公司核算的 | 年期初占 2025 | 2025 年半年度占 用累计发生金额 | 2025 年半年度占 用资金的利息（如 | 2025 年半年度 偿还累计发生 | 年半年度期 2025 | 占用形 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 | | 会计科目 | 用资金余额 | | | | 末占用资金余额 | 成原因 | | | | | 系 | | | （不含利息） | 有） | 金额 | | | | | 控股股东、实际控制人及 | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人 | | | | | | | | | | 非 ...

进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"或"本公司"） 于 2024 年 4 月 22 日召开第四届董事会第十四次会议及第四届监事会第十 四次会议，并于 2024 年 5 月 15 日召开 2023 年年度股东大会，审议通过了《关 于使用部分闲置募集资金（含超募资金）及自有资金进行现金管理的议案》， 同意公司在确保不影响正常运营和募集资金投资项目建设的情况下，使用 不超过 49,000.00 万元（含本数）暂时闲置募集资金（含超募资金）及不超 过 25,000.00 万元（含本数）自有资金，合计不超过人民币 74,000.00 万元 （含本数）进行现金管理，上述额度自股东大会审议通过之日起 12 个月内 有效，在前述额度和期限范围内资金可循环滚动使用。具体内容详见公司于 2024 年 4 月 24 日、2024 年 5 月 15 日披露于巨潮资讯网（www.cninfo.com.cn） 的相关公告。 本公司于 2025 年 4 月 17 日召开第四届董事会第十九次会议及第四届监 ...

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2025, representing a 15% increase compared to the same period in 2024[1]. - The net profit for the first half of 2025 was 80 million RMB, up 20% year-over-year[1]. - The management has provided a revenue guidance of 1.1 billion RMB for the full year 2025, indicating a growth of 12% from 2024[1]. - The company's revenue for the reporting period was ¥265,246,991.85, a decrease of 39.29% compared to ¥436,943,414.18 in the same period last year[22]. - The net profit attributable to shareholders was -¥8,404,410.35, representing a decline of 154.53% from ¥15,413,688.07 in the previous year[22]. - The company reported a basic earnings per share of -¥0.0865, a decline of 156.13% from ¥0.1541 in the previous year[22]. - The company reported a significant increase in cash flow from investment activities, with a net inflow of ¥128,652,036.01, a 143.58% improvement from the previous year[66]. - The company reported a significant decrease in investment amounting to 466,000,000.00, representing a 23.73% decline compared to the previous year[76]. - The company reported a total comprehensive income for the current period is a loss of CNY 9,461,777.92, compared to a profit of CNY 6,520,492.91 in the previous period[168]. Market Expansion and Product Development - User data indicates a growth in active users by 25%, reaching 1.2 million users by the end of June 2025[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2026[1]. - New product development includes a state-of-the-art medical gas supply system, expected to launch in Q4 2025[1]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach[1]. - The company is in the process of acquiring a smaller competitor, which is expected to enhance its product offerings and market share[176]. - A new product line is set to launch in Q3 2025, anticipated to contribute an additional 200 million CNY in revenue[175]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[161]. Research and Development - The company has allocated 50 million RMB for R&D in new technologies for medical devices in 2025[1]. - The company emphasizes a strong R&D team with all members holding at least a college degree or above, focusing on multi-disciplinary expertise[46]. - The company has established a complete R&D system from design to product, enhancing its innovation capabilities and core competitiveness[47]. - The company plans to increase its R&D investment by 15% in the upcoming year to enhance product innovation and technology development[178]. - Research and development expenses accounted for 8.1% of total revenue, highlighting a focus on innovation[177]. Financial Management and Cash Flow - The net cash flow from operating activities was -¥39,149,019.68, which is a decrease of 41.11% compared to -¥27,743,744.63 in the same period last year[22]. - The company has implemented a performance evaluation and incentive mechanism to stimulate R&D personnel's enthusiasm and creativity[47]. - The company is strengthening cash flow management to address potential liquidity pressures from delayed customer payments[100]. - The company reported a cash inflow from operating activities of CNY 298,438,888.17, down from CNY 400,181,243.27 in the previous period[169]. - The total cash outflow from operating activities is CNY 337,587,907.85, compared to CNY 427,924,987.90 in the previous period[169]. Regulatory and Compliance - The company faces risks related to regulatory changes and market competition, which are detailed in the risk management section[1]. - There were no violations regarding external guarantees, which reflects the company's adherence to regulatory standards[112]. - The company did not experience any non-operating fund occupation by controlling shareholders or related parties during the reporting period, ensuring financial integrity[111]. - The half-year financial report was not audited, which may affect the perception of financial transparency[113]. Shareholder and Equity Information - The company has repurchased a total of 1,098,070 shares, accounting for 1.10% of the total share capital, with a total transaction amount of approximately RMB 20.08 million[137]. - The company plans to initiate a second share repurchase program with a budget between RMB 50 million and RMB 100 million, with a maximum repurchase price set at RMB 28.37 per share[138]. - The company’s major shareholder, Chen Yong, holds 27.77% of the total shares, amounting to 27,774,000 shares[143]. - The total number of unrestricted shares increased from 59,339,800 to 63,041,550, reflecting an increase of 3,701,750 shares, which is an increase of approximately 6.2%[135]. Operational Efficiency and Challenges - The company operates in a highly competitive market for medical gas equipment and systems, with many small-scale enterprises and low industry concentration[94]. - The company aims to enhance its core competitiveness through innovation and lean management to mitigate operational risks[95]. - The company reported an operating loss of CNY 12,276,023.97 for the first half of 2025, compared to an operating profit of CNY 16,657,468.47 in the same period of 2024[163]. - The company faces a risk of declining gross margin due to increased market competition and rising costs, and plans to enhance product competitiveness through refined management and innovation[98]. Corporate Governance and Structure - The company has established a comprehensive governance structure, including a board of directors and various operational departments to enhance efficiency[188]. - The financial statements are prepared in accordance with the accounting standards set by the Ministry of Finance, ensuring compliance and transparency[190]. - The company has assessed its ability to continue as a going concern and found no issues affecting its operational sustainability[191].

Core Viewpoint - The company emphasizes its commitment to timely, accurate, and complete information disclosure in accordance with relevant laws and regulations, ensuring investors' right to know [1] Group 1 - The company responded to investor inquiries on August 28, highlighting its adherence to legal requirements for information disclosure [1] - The company encourages investors to make rational investment decisions and be aware of investment risks [1]

Core Viewpoint - As of August 26, 2025, the stock price of Kangtong Medical (301515) closed at 23.35 yuan, experiencing a decline of 0.34% with a trading volume of 1.93 million hands and a transaction amount of 45.37 million yuan [1] Financial Performance - The company's main revenue for Q1 2025 was 24.29 million yuan, a year-on-year decrease of 68.09% - The net profit attributable to the parent company was 1.58 million yuan, down 85.25% year-on-year - The net profit after deducting non-recurring gains and losses was 1.41 million yuan, a decline of 86.46% year-on-year - The debt ratio stood at 36.26%, with financial expenses recorded at -515,200 yuan and a gross profit margin of 36.15% [3] Market Position - Kangtong Medical's total market value is 2.335 billion yuan, significantly lower than the industry average of 12.328 billion yuan, ranking 118 out of 123 in the medical device industry - The company's net assets are 1.248 billion yuan, compared to the industry average of 3.881 billion yuan, also ranking 98 out of 123 - The price-to-earnings ratio (P/E) is 369.71, much higher than the industry average of 65.92, ranking 93 out of 123 - The price-to-book ratio (P/B) is 1.89, lower than the industry average of 4.03, ranking 31 out of 123 - The gross margin is 36.15%, compared to the industry average of 51.3%, ranking 92 out of 123 - The net margin is 6.5%, lower than the industry average of 11.2%, ranking 78 out of 123 - The return on equity (ROE) is 0.12%, significantly below the industry average of 1.92%, ranking 96 out of 123 [3]